159 related articles for article (PubMed ID: 35835035)
1. Rituximab in juvenile myasthenia gravis-an international cohort study and literature review.
Ramdas S; Della Marina A; Ryan MM; McWilliam K; Klein A; Jacquier D; Alabaf S; Childs AM; Parasuraman D; Beeson D; Palace J; Jungbluth H
Eur J Paediatr Neurol; 2022 Sep; 40():5-10. PubMed ID: 35835035
[TBL] [Abstract][Full Text] [Related]
2. The Clinical Course and Treatment of a Case of Refractory Systemic Juvenile Myasthenia Gravis Successfully Treated with Thymectomy.
Shibuya M; Shichiji M; Ikeda M; Kodama K; Miyabayashi T; Sato R; Okubo Y; Endo W; Inui T; Togashi N; Nagao M; Sato K; Sato T; Kanzaki M; Segawa O; Masui K; Ishigaki K; Haginoya K
Tohoku J Exp Med; 2024 Jan; 262(1):29-31. PubMed ID: 37967941
[TBL] [Abstract][Full Text] [Related]
3. Rituximab as Adjunct Maintenance Therapy for Refractory Juvenile Myasthenia Gravis.
Zingariello CD; Elder ME; Kang PB
Pediatr Neurol; 2020 Oct; 111():40-43. PubMed ID: 32951658
[TBL] [Abstract][Full Text] [Related]
4. Management of Juvenile Myasthenia Gravis.
O'Connell K; Ramdas S; Palace J
Front Neurol; 2020; 11():743. PubMed ID: 32793107
[TBL] [Abstract][Full Text] [Related]
5. Clinical features and evolution of juvenile myasthenia gravis in a French cohort.
Barraud C; Desguerre I; Barnerias C; Gitiaux C; Boulay C; Chabrol B
Muscle Nerve; 2018 Apr; 57(4):603-609. PubMed ID: 28877546
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of thymectomy in juvenile myasthenia gravis and clinical characteristics associated with better outcomes.
Ng WC; Hartley L
Neuromuscul Disord; 2021 Nov; 31(11):1113-1123. PubMed ID: 34756789
[TBL] [Abstract][Full Text] [Related]
7. Juvenile myasthenia gravis: a twenty-year experience.
Castro D; Derisavifard S; Anderson M; Greene M; Iannaccone S
J Clin Neuromuscul Dis; 2013 Mar; 14(3):95-102. PubMed ID: 23492460
[TBL] [Abstract][Full Text] [Related]
8. Rituximab in Myasthenia Gravis- Experience from a Low- and Middle-Income Country (LMIC) Setting.
Shivaram S; Nagappa M; Varghese N; Seshagiri DV; Duble S; Siddappa SA; Hesarur N; Sinha S; Taly AB
Neurol India; 2022; 70(5):1931-1941. PubMed ID: 36352590
[TBL] [Abstract][Full Text] [Related]
9. Juvenile Myasthenia Gravis in North Texas: Clinical Features, Treatment Response, and Outcomes.
Lu M; Reisch J; Iannaccone S; Batley K
Pediatr Neurol; 2024 Jul; 156():10-14. PubMed ID: 38688232
[TBL] [Abstract][Full Text] [Related]
10. Rituximab Therapy in the Treatment of Juvenile Myasthenia Gravis: The French Experience.
Molimard A; Gitiaux C; Barnerias C; Audic F; Isapof A; Walther-Louvier U; Cances C; Espil-Taris C; Davion JB; Quijano-Roy S; Grisel C; Chabrol B; Desguerre I
Neurology; 2022 Jun; 98(23):e2368-e2376. PubMed ID: 35314497
[TBL] [Abstract][Full Text] [Related]
11. Rituximab as induction therapy in refractory myasthenia gravis: 18 month follow-up study.
Singh N; Goyal V
J Neurol; 2019 Jul; 266(7):1596-1600. PubMed ID: 30919039
[TBL] [Abstract][Full Text] [Related]
12. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome.
Maddison P; McConville J; Farrugia ME; Davies N; Rose M; Norwood F; Jungbluth H; Robb S; Hilton-Jones D
J Neurol Neurosurg Psychiatry; 2011 Jun; 82(6):671-3. PubMed ID: 20392977
[TBL] [Abstract][Full Text] [Related]
13. The role of thymectomy in the treatment of juvenile myasthenia gravis: a systematic review.
Madenci AL; Li GZ; Weil BR; Zurakowski D; Kang PB; Weldon CB
Pediatr Surg Int; 2017 Jun; 33(6):683-694. PubMed ID: 28401300
[TBL] [Abstract][Full Text] [Related]
14. Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis.
Brauner S; Eriksson-Dufva A; Hietala MA; Frisell T; Press R; Piehl F
JAMA Neurol; 2020 Aug; 77(8):974-981. PubMed ID: 32364568
[TBL] [Abstract][Full Text] [Related]
15. Durability of the Rituximab Response in Acetylcholine Receptor Autoantibody-Positive Myasthenia Gravis.
Robeson KR; Kumar A; Keung B; DiCapua DB; Grodinsky E; Patwa HS; Stathopoulos PA; Goldstein JM; O'Connor KC; Nowak RJ
JAMA Neurol; 2017 Jan; 74(1):60-66. PubMed ID: 27893014
[TBL] [Abstract][Full Text] [Related]
16. Spontaneous remission in juvenile myasthenia gravis: A cohort of 13 cases and review of the literature.
Arroyo HA; Torres AR
Neuromuscul Disord; 2022 Mar; 32(3):213-219. PubMed ID: 35094888
[TBL] [Abstract][Full Text] [Related]
17. Response to treatment in pediatric ocular myasthenia gravis.
Xu L; Castro D; Reisch JS; Iannaccone ST
Muscle Nerve; 2020 Feb; 61(2):226-230. PubMed ID: 31650555
[TBL] [Abstract][Full Text] [Related]
18. Juvenile myasthenia gravis in Norway: A nationwide epidemiological study.
Popperud TH; Boldingh MI; Brunborg C; Faiz KW; Heldal AT; Maniaol AH; Müller KI; Rasmussen M; Øymar K; Kerty E
Eur J Paediatr Neurol; 2017 Mar; 21(2):312-317. PubMed ID: 27666466
[TBL] [Abstract][Full Text] [Related]
19. Outcome of children with acetylcholine receptor (AChR) antibody positive juvenile myasthenia gravis following thymectomy.
Heng HS; Lim M; Absoud M; Austin C; Clarke D; Wraige E; Reid C; Robb SA; Jungbluth H
Neuromuscul Disord; 2014 Jan; 24(1):25-30. PubMed ID: 24239058
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis.
Iorio R; Damato V; Alboini PE; Evoli A
J Neurol; 2015 May; 262(5):1115-9. PubMed ID: 25308632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
